Subscribe To
High-sensitivity troponin assays may stratify risk in chronic cad
An exploratory analysis suggests an elevated troponin level may identify patients who would benefit from revas...
August 1, 2023, 4:03 pm
More angina relief with complete revascularization in stable cad: ischemia
Complete revascularization with PCI results in better health status for patients with multivessel, stab...
July 18, 2023, 8:59 pm
Amarin announces new reduce-it® data at acc.23/wcc showing benefit of vascepa®/vazkepa® (icosapent ethyl) in high-risk patients with a recent acute coronary syndrome event
–Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS With...
March 5, 2023, 3:21 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm